Inclusion Criteria:

1. histologically or cytologically confirmed non-small cell bronchogenic carcinoma,
inoperable stage IIIB or IV

2. aged 18 years or older

3. failed previous platinum-based chemotherapy

4. presence of at least one measurable disease which is defined as lesion that can be
measured in at least 1 dimension as ≥ 20 mm with conventional CT or ≥ 10 mm with
spiral CT scan

5. performance status of Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2

6. white blood cell (WBC) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3,
platelets ≥ 100,000/mm3 and hemoglobin ≥ 10 mg / dl

7. serum creatinine level 2.0 mg/dL or lower

8. serum bilirubin less than 1.5 times the upper limit of normal range (ULN)

9. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 3 times
the ULN (less than 5 times the ULN in liver metastases)

10. written informed consent to participate in the trial In addition, in female patient
with childbearing potential, either terminated by surgery, radiation, or menopause,
or attenuated by use of an approved contraceptive method (intrauterine contraceptive
device [IUD], birth control pills, or barrier device) during and for three months
after trial. Patients who previously treated by surgery are needed to demonstrate
progressive disease before entering the study.

Exclusion Criteria:

1. Active infection (at the discretion of the investigator).

2. Active central nervous system (CNS) metastases.

3. Breast feeding.

4. Serious concomitant systemic disorders incompatible with the study (at the discretion
of the investigator).

5. Use of any investigational agent in the month before enrollment into the study.

6. Concomitant myelosuppressive radiotherapy to target lesion, chemotherapy, hormonal
therapy, or immunotherapy will not be allowed.